该试验预计将于2022年启动,其结果将为TAEUS装置在中国用于NAFLD的潜在商业化提供临床证据。
ENDRA(NDRA)首席执行官弗朗索瓦·米其隆(Francois Michelon)表...查看全文
智通财经APP预告,2021年5月18日,港美股上市公司活动及香港重要财经会议信息情况如下: 04:30 ENDRA Life Sciences, Inc.(NDRA.US) ENDRA Life Sciences, Inc.(NDRA.US)2021年第一季度业绩电话会 网络转播 04:30 GAN Limited(GAN.US) G... 网页链接
$Endra Life Sciences(NDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-19-060086 Size: 5 KB 网页链接
$Endra Life Sciences(NDRA)$ 8-K Current report, items 1.01, 3.02, 7.01, and 9.01 Accession Number: 0001654954-19-013822 Act: 34 Size: 514 KB 网页链接
$Endra Life Sciences(NDRA)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001654954-19-012855 Act: 34 Size: 2 MB 网页链接
$Endra Life Sciences(NDRA)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001654954-19-012843 Act: 34 Size: 284 KB 网页链接
$Endra Life Sciences(NDRA)$ 424B7 - Prospectus [Rule 424(b)(7)] Filed: 2019-09-16 AccNo: 0001654954-19-010771 Size: 644 KB 网页链接
$Endra Life Sciences(NDRA)$ EFFECT - Notice of Effectiveness Filed: 2019-09-13 AccNo: 9999999995-19-002092 Size: 1 KB 网页链接
$Endra Life Sciences(NDRA)$ S-3 - Registration statement under Securities Act of 1933 Filed: 2019-08-26 AccNo: 0001654954-19-010005 Size: 772 KB 网页链接
$Endra Life Sciences(NDRA)$ 8-K - Current report Filed: 2019-08-16 AccNo: 0001654954-19-009726 Size: 26 KBItem 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 网页链接
$Endra Life Sciences(NDRA)$ S-8 - Securities to be offered to employees in employee benefit plans Filed: 2019-08-09 AccNo: 0001654954-19-009167 Size: 123 KB 网页链接
$Endra Life Sciences(NDRA)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2019-08-08 AccNo: 0001654954-19-009079 Size: 2 MB 网页链接